Background:
2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis has been used as an inflammatory bowel disease (IBD), Crohn's disease (CD), preclinical model. However, published data on pharmacologic and therapeutic efficacy testing of this model are limited. FTY720 inhibits lymphoid cell trafficking in inflammatory conditions and is of interest to treat IBD.
Aim:
We investigated the pharmacologic therapeutic efficacy of sulfasalazine, FTY720, and anti-IL-12/23p40, in a TNBS CD model.
Methods:
Female, 7-week-old, BALB/c mice were given sulfasalazine orally (PO) and intraperitoneally (IP) at 10 mg/kg, FTY720 at 3 mg/kg PO, and mouse anti-IL-12/23p40 at 25 mg/kg IP. Vehicle groups given PO either phosphate-buffered saline/water or 40% ethanol served as controls. Pharmacologic efficacy was assessed using body weight loss, clinical scores of diarrhea and intestinal gross pathology, and colon weight parameters.
Results:
Sulfasalazine and FTY720 treatment did not prevent body weight loss or reduce clinical scores of diarrhea or intestinal gross pathology, when compared with vehicle treatment. However, anti-IL-12/23p40 treatment showed significant efficacy by preventing body weight loss, reducing clinical scores of diarrhea, and reducing intestinal gross pathologic lesions, when compared with vehicle-treated animals. Sulfasalazine, anti-IL-12/23p40, and FTY720 were not effective in reducing colon weight.
Conclusion:
With the exception of anti-IL-12/23p40, sulfasalazine, and FTY720 did not demonstrate full pharmacologic efficacy in our TNBS CD model.
Citing Articles
Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer.
Espinoza K, Snider A
Cancers (Basel). 2024; 16(4).
PMID: 38398179
PMC: 10887199.
DOI: 10.3390/cancers16040789.
[Pachymic acid protects against Crohn's disease-like intestinal barrier injury and colitis in miceby suppressingintestinal epithelial cell apoptosis inhibiting PI3K/AKT signaling].
Shao R, Yang Z, Zhang W, Zhang N, Zhao Y, Zhang X
Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(6):935-942.
PMID: 37439165
PMC: 10339296.
DOI: 10.12122/j.issn.1673-4254.2023.06.08.
[Diosmetin regulates intestinal immune balance by inhibiting PI3K/AKT signaling to relieve 2, 4, 6-trinitrobenzene sulfonic acid-induced Crohn's disease-like colitis in mice].
Yang Z, Zhao T, Cheng Y, Zhou Y, Li Y, Wang X
Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(3):474-482.
PMID: 37087594
PMC: 10122747.
DOI: 10.12122/j.issn.1673-4254.2023.03.19.
Chemically Induced Colitis-Associated Cancer Models in Rodents for Pharmacological Modulation: A Systematic Review.
Modesto R, Estarreja J, Silva I, Rocha J, Pinto R, Mateus V
J Clin Med. 2022; 11(10).
PMID: 35628865
PMC: 9146029.
DOI: 10.3390/jcm11102739.
Chronic Sulfasalazine Treatment in Mice Induces System x - Independent Adverse Effects.
Verbruggen L, Sprimont L, Bentea E, Janssen P, Gharib A, Deneyer L
Front Pharmacol. 2021; 12:625699.
PMID: 34084129
PMC: 8167035.
DOI: 10.3389/fphar.2021.625699.
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Perez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J
Drugs. 2021; 81(9):985-1002.
PMID: 33983615
PMC: 8116828.
DOI: 10.1007/s40265-021-01528-8.
MicroRNA-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses in inflammatory bowel disease.
Shi Y, Dai S, Qiu C, Wang T, Zhou Y, Xue C
Mucosal Immunol. 2019; 13(2):303-312.
PMID: 31628427
DOI: 10.1038/s41385-019-0216-7.
Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis.
Silva I, Pinto R, Mateus V
J Clin Med. 2019; 8(10).
PMID: 31581545
PMC: 6832474.
DOI: 10.3390/jcm8101574.
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
Perez-Jeldres T, Tyler C, Boyer J, Karuppuchamy T, Yarur A, Giles D
Front Pharmacol. 2019; 10:212.
PMID: 30930775
PMC: 6425155.
DOI: 10.3389/fphar.2019.00212.
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
Perez-Jeldres T, Tyler C, Boyer J, Karuppuchamy T, Bamias G, Dulai P
Inflamm Bowel Dis. 2018; 25(2):270-282.
PMID: 30165490
PMC: 6327230.
DOI: 10.1093/ibd/izy269.
Frontiers in Drug Research and Development for Inflammatory Bowel Disease.
Curro D, Pugliese D, Armuzzi A
Front Pharmacol. 2017; 8:400.
PMID: 28690543
PMC: 5481609.
DOI: 10.3389/fphar.2017.00400.
Sphingosine-1-phosphate receptor-1 (S1P) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease.
Karuppuchamy T, Behrens E, Gonzalez-Cabrera P, Sarkisyan G, Gima L, Boyer J
Mucosal Immunol. 2016; 10(1):162-171.
PMID: 27049060
PMC: 5053832.
DOI: 10.1038/mi.2016.35.
TLR4 regulates IFN-γ and IL-17 production by both thymic and induced Foxp3+ Tregs during intestinal inflammation.
Cao A, Yao S, Stefka A, Liu Z, Qin H, Liu H
J Leukoc Biol. 2014; 96(5):895-905.
PMID: 25015957
PMC: 4197555.
DOI: 10.1189/jlb.3A0114-056RR.
Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease.
Snider A
Int J Clin Rheumtol. 2014; 8(4).
PMID: 24416079
PMC: 3883358.
DOI: 10.2217/ijr.13.40.
Green Tea Polyphenols and Sulfasalazine have Parallel Anti-Inflammatory Properties in Colitis Models.
Oz H, Chen T, de Villiers W
Front Immunol. 2013; 4:132.
PMID: 23761791
PMC: 3672863.
DOI: 10.3389/fimmu.2013.00132.
